^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

    Excerpt:
    ...Evaluated by researchers based on the RECIST 1.1 standard`Objective remission rate (ORR)`Progression free survival (PFS)`Overall survival (OS)`The number of Circulating Tumor Cell (CTC)`Analysis of PD-L1 expression on Circulating Tumor Cell (CTC) and tumor tissue...
    Trial ID:
    NCT04239443
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial

    Published date:
    03/01/2023
    Excerpt:
    We aimed to assess the activity and safety of neoadjuvant camrelizumab plus apatinib in patients with resectable NSCLC….Among the 65 patients, 37 (57%, 95% confidence interval [CI]: 44%-69%) had an MPR, of whom 15 (23%, 95% CI: 14%-35%) had a pathologic complete response (pCR)...baseline programmed death-ligand 1 expression, HOXA9 and SEPT9 methylation levels, and circulating tumor DNA status before surgery were associated with pathologic responses.
    DOI:
    10.1016/j.jtho.2023.02.019